• Releasing the Potential of Biobatteries

    Bio-IT World | Imagine batteries made from completely safe, organic, non-combustible, and biodegradable materials. Now imagine that these batteries can be recharged not from an outlet, but from the excess energy of our bodies. Refueling by gathering kinetic energy from our movement, or thermal energy from body heat, or—in what might be the most sci-fi scenario—feeding on the biochemical surplus of sugars coursing through our veins, or even compounds present in our saliva, sweat, or other body fluids. This idea is the biobattery, and the potential uses and benefits are pretty remarkable.

    Feb 9, 2022

  • Follow the Money: AI in Gastroenterology Research, Cloud Infrastructure Provisioning

    Bio-IT World | Sanofi and Exscientia collaborate to use AI for oncology and immunology treatments, Iterative Scopes using AI in gastroenterology treatments, Quris uses AI for clinical prediction, and more.

    Feb 8, 2022

  • Driving Value in Biopharma R&D through Digital Transformation

    Bio-IT World | Rapid scientific innovation is dependent on streamlining three key capabilities: improving data usability, enabling global cross-team collaboration, and automating scientific workflows. We believe that digital technologies should serve as the foundation that connects your data, people, and processes together to drive scientific discovery. From our perspective, the companies that embrace digital will ultimately win the R&D race.

    Feb 4, 2022

  • New Collaborations to Address Skin Care, Gastrointestinal Disease, MS, Whole-Cell Models, Spatial Genomics

    Bio-IT World | Skin health, particle-scale whole-cell models with NVIDIA, single-cell spatial genomics, diabetic kidney disease. Plus: AI in MS, inflammatory bowel disease, clinical trials, and genomic searches, and more.

    Feb 2, 2022

  • Novel CAR T Cells Give Cancer A One-Two Punch

    Bio-IT World | In an entirely new direction for immunotherapy, researchers at the Sloan Kettering Institute (SKI) have genetically engineered chimeric antigen receptor (CAR) T cells to produce potentially synergistic, small-molecule drugs that can penetrate a solid tumor.

    Feb 1, 2022

  • Illumina, Invitae Founding Members of ASHG’s Genetics and Genomics Impact Partnerships Program

    Bio-IT World | The American Society of Human Genetics (ASHG) today announced the launch of the ASHG Genetics and Genomics Impact Partnerships program. Illumina, a leader in next-generation genomic sequencing technologies, and Invitae, a leading medical genetics company, have joined as founding partners.

    Jan 31, 2022

  • Predicting COVID-19 Severity: Researchers Look to Fill Diagnostic Gap, Match Patients with Treatments

    Bio-IT World | Researchers at Mount Sinai and the University of Colorado are pursuing the possibilities that stem from predicting which COVID-19 patients are most likely to deteriorate over time. The hope is that this ability could help health care professionals more effectively triage patients and pair them with appropriate treatments to improve outcomes.

    Jan 27, 2022

  • Data Contributors Wield Control In AI-Powered Longevity Research Network

    Bio-IT World | Efforts are underway to create an economy of data contributors and researchers who want to retain ownership of their contribution to longevity research as well as a proportionate share of the downstream profits from any resulting products. The ecosystem, and tokens underpinning it, goes by the name of Rejuve—definitionally, “the process of making somebody young again.”

    Jan 26, 2022

  • Canadian Brain Institute Opens Data Sharing on Alzheimer’s, Parkinson’s, More

    Bio-IT World | After a decade of methodical preparation, Canada’s Ontario Brain Institute's (OBI) neuroinformatics platform, Brain-CODE, launched its open data sharing feature for global brain disorder research.

    Jan 25, 2022

  • The Role Of Bioinformatics In Bringing Biobanks To The Forefront Of Scientific Breakthroughs

    Bio-IT World | Life science researchers and drug discovery scientists today work in what, in my view, will be remembered in the future as the beginning of a “golden era” where the power of genetic information is connected to a wide range of other healthcare and lifestyle data to support better understanding of disease etiology, as well as the identification of candidates for drug targets and the discovery of new biomarkers that can be used to predict the presence or future development of a disease in an individual patient.

    Jan 21, 2022

  • Human Proteoform Project Could Be Biology’s Next Moonshot

    Bio-IT World | The nonprofit Consortium for Top-Down Proteomics recently proposed the Human Proteoform Project to generate a definitive reference set of the proteoforms produced from the genome. This will become a “seminal moment in science,” Neil Kelleher says, and the initiative is the next obvious step now that the Human Genome Project has provided the blueprint for how proteins get made.

    Jan 19, 2022

  • Applying AI to Real-World Data to Improve Pharmaceutical Development

    Bio-IT World | Trends from the Trenches —Xiong Sean Liu is a Director at Novartis where he has been working to make inroads for AI in pharma. In Liu’s view, AI as a technology is already successful, but he also believes it is still in its early days for healthcare and there are still significant challenges for use. Data organization, for example, must be solved so that AI models can be put to best use. Liu and his team recently explored how electronic health records could be better populated and curated to facilitate clinical trials.

    Jan 18, 2022

  • PacBio Plugs Partnerships, Accuracy at JP Morgan

    Bio-IT World | Closing out the genomic presentations at the JP Morgan Healthcare Conference, Christian Henry, president and CEO of Pacific Biosciences, had the dual challenges of presenting PacBio’s year and future strategies as well as answering claims and announcements other companies made. He persevered.

    Jan 14, 2022

  • Antibodies, Easy Single-Cell, Genomics for All: Notes from the JP Morgan Healthcare Conference

    Bio-IT World | At the JP Morgan Healthcare Conference—being held virtually again this year—pharma and biotech companies gave overviews of their 2021 business and their views of the future. Here are the highlights we noted from presentations from Regeneron, 10X Genomics, and Invitae

    Jan 13, 2022

  • Seqster, National Pancreas Foundation, Launch Pancreatic Disease Patient Registry

    Bio-IT World | Seqster announced today a multi-year partnership with The National Pancreas Foundation, a nonprofit organization that provides hope for those suffering from pancreatitis and pancreatic cancer, to create the country’s largest, most inclusive pancreatic disease patient registry. The registry uses Seqster technology to connect to any EHR, genomic DNA test, and wearable/remote monitoring device, providing patients with a complete longitudinal health record in real-time.

    Jan 11, 2022

  • Illumina Teases New Chemistry, Long Reads, Oncology, Proteomics Partnerships

    Bio-IT World | At the JP Morgan Healthcare Conference—being held virtually again this year—Illumina CEO Francis deSouza outlined Illumina’s record for 2021, announced several new partnerships, and teased new chemistry and new long read technologies.

    Jan 11, 2022

  • Trendspotting: What’s Coming for Bio-IT in 2022

    Bio-IT World | We spoke with several players in the Bio-IT World vendor community to gain insights and predictions for the coming year. They predicted newer ‘omics, green chemistry, SaaS medical devices, federated learning, XNAT, protein sequencing, and more.

    Jan 10, 2022

  • Multiomics Used To Stratify Multiple Myeloma Patients Into Affinity Groups

    Bio-IT World | All new multiple myeloma patients being treated at the Tisch Cancer Institute at Mount Sinai are now being assigned to one of 12 subgroups based on shared genetic and molecular features of their disease. The multiple myeloma patient similarity network (MM-PSN) is one of the latest computational modeling tools being used here to translate clinical data into better treatment decision-making in the clinic, and the first to apply multiomics to the stratification of patients with the blood cancer.

    Jan 6, 2022

  • Overlooked Impact Of Cardiometabolic Drugs On The Gut Microbiome

    Bio-IT World | A large-scale study involving more than 2,000 individuals across three countries could help disentangle associations between cardiometabolic disease, the gut microbiome, and metabolic markers in the blood—and, perhaps most importantly, the potential role played by the most prescribed drug treatments.

    Jan 5, 2022

  • Is Excel Holding Back Biopharmaceutical Research?

    Bio-IT World | Data aggregation and consolidation are essential in biopharmaceutical development. Research teams use a wide range of analytical and sensor data from various instruments, which are often spread across multiple sites. These data streams need a common platform to allow scientists to review the data and make decisions. Excel is used to perform this consolidation in many companies, but while access to Excel is convenient, this software is the root cause of many data management problems.

    Jan 3, 2022